Vitamin D, infections and immune-mediated diseases

International Journal of Clinical Rheumatology

Volumn 4, Issue 1, 2009, Pages 89-103

  Armas, Laura AG ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1,25 Dihydroxyvitamin D; 25 Hydroxyvitamin D; Autoimmune; Immunity; Infection; Vitamin D

Indexed keywords

19 NOR 1,25 DIHYDROXYVITAMIN D2; CALCITRIOL; CALCIUM; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

AUTOIMMUNE DISEASE; BONE; CALCIUM METABOLISM; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; ENTERITIS; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INTERNET; MEDICAL INFORMATION; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOMALACIA; PHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; RHEUMATOID ARTHRITIS; RICKETS; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 71049157632     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/17584272.4.1.89     Document Type: Review

References (132)

1. Thomas KK, Lloyd-Jones DM, Thadhani RI et al.: Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 338, 777-783 (1998).
2. Chapuy MC, Preziosi P, Maamer M et al.: Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 7, 439-443 (1997).
3. Holick MF, Siris ES, Binkley N et al.: Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J. Clin. Endocrinol. Metab. 90, 3215-3224 (2005).
4. Heaney RP, Dowell MS, Hale CA, Bendich A: Calcium absorptirron varies within the reference range for serum 25- hydroxyvitamin D. J. Am. Coll. Nutr. 22, 142-146 (2003).
5. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ: Prevalence of vitamin D deficiency among healthy adolescents. Arch. Pediatr. Adolesc. Med. 158, 531-537 (2004).
6. Sullivan SS, Rosen CJ, Halteman WA, Chen TC, Holick MF: Adolescent girls in Maine at risk for vitamin D insufficiency. J. Am. Diet. Assoc. 105, 971-974 (2005).
7. Tangpricha V, Pearce EN, Chen TC, Holick MF: Vitamin D insufficiency among free-living healthy young adults. Am. J. Med. 112, 659-662 (2002).
8. Marwaha RK, Tandon N, Reddy D et al.: Vitamin D and bone mineral density status of healthy schoolchildren in northern India. Am. J. Clin. Nutr. 82, 477-482 (2005).
9. Levis S, Gomez A, Jimenez C et al.: Vitamin D deficiency and seasonal variation in an adult south Florida population. J. Clin. Endocrinol. Metab. 90(3), 1557-1562 (2005).
10. Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers and cardiovascular disease. Am. J. Clin. Nutr. 80(6 Suppl.), 1678S-1688S (2004).
11. Holick MF: Vitamin D for health and in chronic kidney disease. Semin. Dial. 18, 266-275 (2005).
12. Wayse V, Yousafzai A, Mogale K, Filteau S: Association of subclinical vitamin D deficiency with severe acute lower respiratory infection in Indian children under 5 y. Eur. J. Clin. Nutr. 58, 563-567 (2004).
13. Bringhurst F, Demay M, Kronenberg H: Hormones and disorders of mineral metabolism. In: Williams Textbook of Endocrinology (11th Edition). Kronenberg HM, Melmed S, Polonsky KS, Larsen PR (Eds). WB Saunders Company, PA, USA, 1155-1209 (2008).
14. Liu PT, Stenger S, Li H et al.: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770-1773 (2006).
15. Herr C, Shaykhiev R, Bals R: The role of cathelicidin and defensins in pulmonary inflammatory diseases. Expert Opin. Biol. Ther. 7, 1449-1461 (2007).
16. Howell MD, Wollenberg A, Gallo RL et al.: Cathelicidin deficiency predisposes to eczema herpeticum. J. Allergy Clin. Immunol. 117, 836-841 (2006).
17. Laube DM, Yim S, Ryan LK, Kisich KO, Diamond G: Antimicrobial peptides in the airway. Curr. Top. Microbiol. Immunol. 306, 153-182 (2006).
18. Mahon BD, Wittke S, Weaver V, Cantorna MT: The targets of vitamin D depend on the differentiation and activation status of CD4-positive T cells. J. Cell. Biochem. 89, 922-932 (2003).
19. Cantorna MT, Zhu Y, Froicu M, Wittke A: Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am. J. Clin. Nutr. 80, 1717S-1720S (2004).
20. Patel S, Farragher T, Berry J, Bunn D, Silman A, Symmons D: Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum. 56, 2143-2149 (2007).
21. Nashold FE: Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 119, 16-29 (2001).
22. Mathieu C, Badenhoop K: Vitamin D and Type 1 diabetes mellitus: state of the art. Trends Endocrinol. Metab. 16, 261-266 (2005).
23. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE: Modulatory effects of 1,25-hydroxyvitamin D3 on human B cell differentiation. J. Immunol. 179, 1634-1647 (2007).
24. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R: Dendrtic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor- dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 6800-6805 (2001).
25. Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R: Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem. Biophys. Res. Commun. 270, 701-708 (2000).
26. Sigmundsdottir H, Butcher EC: Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat. Immunol. 9, 981-987 (2008).
27. Helming L, Bose J, Ehrchen J et al.: 1α,25-dihydroxyvitamin D3 is a potent suppressor of interferon-mediated macrophage activation. Blood 106, 4351-4358 (2005).
28. Mattner F: Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur. J. Immunol. 30, 498-508 (2000).
29. D'Ambrosio D, Cippitelli M, Cocciolo MG et al.: Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3: involvement of NF-κB downregulation in transcriptional repression of the p40 gene. J. Clin. Invest. 101, 252-262 (1998).
30. Arnson Y, Amital H, Shoenfeld Y: Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann. Rheum. Dis. 66, 1137-1142 (2007).
31. Raab W: Vitamin D - its bactericidal action. Chest 12, 409-415 (1946).
32. Rook GA, Steele J, Fraher L et al.: Vitamin D3, interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57, 159-163 (1986).
33. Wilkinson RJ, Llewelyn M, Toossi Z et al.: Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis amongst Gujarati Asians in West London: a case-control study. Lancet 355, 618-621 (2000).
34. Gibney KB, MacGregor L, Leder K et al.: Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin. Infect. Dis. 46(3), 443-446 (2008).
35. Nursyam EW, Amin Z, Rumende CM: The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med. Indones. 38, 3-5 (2006).
36. Maerineau AR, Wilinson RJ, Wilkinson KA et al.: A single dose of vitamin D enhances immunity to mycobacteria. Am. J. Respir. Crit. Care Med. 176, 208-213 (2007).
37. Cannell JJ, Vieth R, Umhau C et al.: Epidemic influenza and vitamin D. Epidemiol. Infect. 134, 1129-1140 (2006).
38. Cannell JJ, Zasloff M, Garland F, Scragg R, Giovannucci E: On the epidemiology of influenza. Virol. J. 5, 29 (2008).
39. Muhe L, Lulseged S, Mason KE, Simoes EAF: Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet 349, 1801-1804 (1997).
40. Laaksi I, Ruohola JP, Tuohimaa P et al.: An association of serum vitamin D concentrations <40 nmol/l with acute respiratory tract infection in young Finnish men. Am. J. Clin. Nutr. 86, 714-717 (2007).
41. Aloia JF, Li-Ng M: Re: epidemic influenza and vitamin D. Epidemiol. Infect. 134, 1129-1130 (2007).
42. Kawarau A, Takeda N, Tanida K et al.: Inhibitory effect of long term 1-(-hydroxyvitamin D3 administration on Helicobacter pylori infection. J. Clin. Biochem. Nutr. 38, 103-106 (2006).
43. Grant WB: Epidemiology of disease risks in relation to vitamin D insufficiency. Prog. Biophys. Mol. Biol. 92, 65-79 (2006).
44. Embry AF, Snowdon LR, Vieth R: Vitamin D and seasonal fluctuations of gadolinium- enhancing lesions in multiple sclerosis. Ann. Neurol. 48, 271-272 (2000).
45. Lin R, White JH: The pleiotropic actions of vitamin D. Bioessays 26, 21-28 (2004).
46. Loftus EV Jr: Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126, 1504-1517 (2004).
47. Moum B, Aadland E, Ekbom A, Vatn MH: Seasonal variations in the onset of ulcerative colitis. Gut 38, 376-378 (1996).
48. Siffledeen JS, Siminoski K, Steinhart H, Greenberg G, Fedorak RN: The frequency of vitamin D deficiency in adults with Crohn's disease. Can. J. Gastroenterol. 17, 473-478 (2003).
49. Leslie WD, Miller N, Rogala L, Bernstein CN: Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am. J. Gastroenterol 103, 1451-1459 (2008).
50. Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS: Vitamin D status in children, adolescents, and young adults with Crohn disease. Am. J. Clin. Nutr. 76, 1077-1081 (2002).
51. Pappa HM, Gordon CM, Saslowsky TM et al.: Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics 118, 1950-1961 (2006).
52. Pappa HM, Grand RJ, Gordon CM: Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm. Bowel Dis. 12, 1162-1174 (2006).
53. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT: A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol. Endocrinol. 17, 2386-2392 (2003).
54. Bises G, Kallay E, Weiland T et al.: 25-hydroxyvitamin D3-1α-hydroxylase expression in normal and malignant human colon. J. Histochem. Cytochem. 52, 985-989 (2004).
55. Cantorna MT, Munsick C, Bemiss C, Mahon BD: 1,25-dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J. Nutr. 130, 2648-2652 (2000).
56. Daniel C, Radeke HH, Sartory NA et al.: The new low calcemic vitamin D analog 22-eme-25-oxa-vitamin D prominently ameliorates T helper cell Type 1-mediated colitis in mice. J. Pharmacol. Exp. Ther. 319, 622-631 (2006).
57. Kikuchi H, Murakami S, Suzuki S, Kudo H, Sassa S, Sakamoto S: Chemopreventive effect of a vitamin D3 analog, alfacalcidol, on colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Drugs 18, 1183-1187 (2007).
58. Zhu Y, Mahon BD, Froicu M, Cantorna MT: Calcium and 1α,25-dihydroxyvitamin D3 target the TNF-( pathway to suppress experimental inflammatory bowel disease. Eur. J. Immunol. 35, 217-224 (2005).
59. Stio M, Martinesi M, Bruni S et al.: Interaction among vitamin D(3) analogue KH 1060, TNF-α, and vitamin D receptor protein in peripheral blood mononuclear cells of inflammatory bowel disease patients. Int. Immunopharmacol. 6, 1083-1092 (2006).
60. + T cells from patients with Crohn's disease. Int. Immunopharmacol. 7, 1755-1764 (2007).
61. Kong J, Zhang Z, Musch MW et al.: Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G208-G216 (2008).
62. Staples JA, Ponsonby AL, Lim LL, McMichael AJ: Ecologic ana lysis of some immune-related disorders, including Type 1 diabetes, in Australia: latitude, regional ultraviolet radiation, and disease prevalence. Environ. Health Perspect. 111, 518-523 (2003).
63. Cantorna MT, Hayes CE, DeLuca HF: 1,25-dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J. Nutr. 128, 68-72 (1998).
64. Oelzner P, Franke S, Muller A, Hein G, Stein G: Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology 38, 841-847 (1999).
65. Iikuni N, Nakajima A, Inoue E et al.: What's in season for rheumatoid arthritis patients? Seasonal fluctuations in disease activity. Rheumatology 46, 846-848 (2007).
66. Cutolo M, Otsa K, Laas K et al.: Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin. Exp. Rheumatol. 24, 702-704 (2006).
67. Oelzner P, Miller A, Deschner F et al.: Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif. Tissue Int. 62, 193-198 (1998).
68. Kroger H, Penttila IM, Alhava EM: Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand. J. Rheumatol. 22, 172-177 (1993).
69. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG: Vitamin D intake is inversely associated with rheumatoid arthritis. Arthritis Rheum. 50, 72-77 (2004).
70. Costenbader KH, Feskanich D, Holmes M, Karlson EW, Benito-Garcia E: Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann. Rheum. Dis. 67, 530-535 (2008).
71. Nielen MMJ, van Schaardenburg D, Lems WF et al.: Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al.: Arthritis Rheum. 54, 3719-3720 (2006).
72. Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B: Vitamin D in rheumatoid arthritis. Autoimmun. Rev. 7, 59-64 (2007).
73. Andjelkovic Z, Vojinovic J, Pejnovic N et al.: Disease modifying and immunomodulatory effects of high dose 1 α(OH)D3 in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 17, 453-456 (1999).
74. Cantorna MT, Mahon BD: Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp. Biol. Med. (Maywood) 229, 1136-1142 (2004).
75. Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A: 25-hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 11, 266-271 (2005).
76. Munger KL, Zhang SM, O'Reilly E et al.: Vitamin D intake and incidence of multiple sclerosis. Neurology 62, 60-65 (2004).
77. Kragt JJ, van Amerongen BM, Killestein J et al.: Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult. Scler. 15(1), 9-15 (2009).
78. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A: Serum 25- hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832-2838 (2006).
79. Cosman F, Nieves J, Komar L et al.: Fracture history and bone loss in patients with MS. Neurology 51, 1161-1165 (1998).
80. Brown SJ: The role of vitamin D in multiple sclerosis. Ann. Pharmacother. 40, 1158-1161 (2006).
81. Wingerchuk DM, Lesaux J, Rice GPA, Kremenchutzky M, Ebers GC: A pilot study of oral calcitriol (1,25(OH)2D3) for relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 76, 1294- 1296 (2005).
82. Achiron A, Barak Y, Miron S et al.: Alfacalcidiol treatment in multiple sclerosis. Clin. Neuropharmacol. 26, 53 (2003).
83. Fleming JO, Hummel AL, Beinlich BR et al.: Vitamin D treatment of relapsing-remitting multiple sclerosis (RRMS): a MRI-based pilot study (abstract). Neurology 54(Suppl. 3), A338 (2000).
84. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT: Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J. Neuroimmunol. 134, 128-132 (2003).
85. Link J, Soderstrom M, Olsson T, Hojeberg B, Ljungdahl A, Link H: Increased transforming growth factor-β, interleukin-4, and interferon-γ in multiple sclerosis. Ann. Neurol. 36, 379-386 (1994).
86. Goldberg P, Fleming MC, Picard EH: Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med. Hypotheses 21, 193-200 (1986).
87. Kimball SM, Ursell MR, O'Connor P, Vieth R: Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr. 86, 645-651 (2007).
88. Bischoff Ferrari HA, Orav EJ, Dawson-Hughes B: Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Arch. Intern. Med. 166, 424-430 (2006).
89. Mohr WB, Garland CF, Gorham ED, Garland FC: The association between ultraviolet B irradiance, vitamin D status and incidence rates of Type 1 diabetes in 51 regions worldwide. Diabetologia 51, 1391-1398 (2008).
90. Keen H, Ekoe JM: The geography of diabetes mellitus. Br. Med. Bull. 40, 359-365 (1984).
91. Luong KVQ, Nguyen LT, Nguyen DN: The role of vitamin D in protecting Type 1 diabetes mellitus. Diabetes Metab. Res. Rev. 21, 338-346 (2005).
92. Sloka S, Grant M, Newhook LA: Time series analysis of ultraviolet B radiation and Type 1 diabetes in Newfoundland. Pediatr. Diabetes 9, 81-86 (2008).
93. Littorin B, Blom P, Schölin A et al.: Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune Type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 49, 2847-2852 (2006).
94. Pozzilli P, Manfrini S, Crinò A et al.; IMDIAB group: Low levels of 25-hydroxyvitamin D3 and 1,25- dihydroxyvitamin D3 in patients with newly diagnosed Type 1 diabetes. Horm. Metab. Res. 37, 680-683 (2005).
95. Greer RM, Rogers MA, Bowling FG et al.: Australian children and adolescents with Type 1 diabetes have low vitamin D levels. Med. J. Aust. 187, 59-60 (2007).
96. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM: Intake of vitamin D and risk of Type 1 diabetes: a birth-cohort study. Lancet 358, 1500-1503 (2001).
97. Brekke HK, Ludvigsson J: Vitamin D supplementation and diabetes-related autoimmunity in the ABIS study. Pediatr. Diabetes. 8, 11-14 (2007).
98. Fronczak CM, Barón AE, Chase HP et al.: In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care 26, 3237-3242 (2003).
99. Stene LC, Joner G; Norwegian Childhood Diabetes Study Group: Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset Type 1 diabetes: a large, population-based case-control study. Am. J. Clin. Nutr. 78, 1128-1134 (2003).
100. Tenconi MT, Devoti G, Comelli M et al.; Pavia T1DM Registry Group: Major childhood infectious diseases and other determinants associated with Type 1 diabetes: a case-control study. Acta Diabetol. 44, 14-19 (2007).
101. Zipitis CS, Akobeng AK: Vitamin D supplementation in early childhood and risk of Type 1 diabetes: a systematic review and meta-ana lysis. Arch. Dis. Child. 93, 512-517 (2008).
102. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R: Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 37, 552-558 (1994).
103. Mathieu C, Laureys J, Sobis H, Vandeputte M, Waer M, Bouillon R: 1,25-dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes 41, 1491-1495 (1992).
104. Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R: Prevention of Type 1 diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology 136, 866-872 (1995).
105. Pedullà M, Desiderio V, Graziano A, d'Aquino R, Puca A, Papaccio G: Effects of vitamin D3 analog on diabetes in the bio breeding (BB) rat. J. Cell. Biochem. 100, 808-814 (2007).
106. Pitocco D, Crinò A, Di Stasio E et al.; on behalf of the IMDIAB group: The effects of calcitriol and nicotinamide on residual pancreatic β-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet. Med. 23, 920-923 (2006).
107. Pozzilli P, Gugliemi C: Immunomodulation for the prevention of SPIDDM and LADA. Ann. NY Acad. Sci. 1079, 90-98 (2006).
108. Abe J, Nakamura K, Takita Y et al.: Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of Vitamin D3: 22-oxa-1 α, 25-dihdroxyvitamin D3. J. Nutr. Sci. Vitaminol. 36, 21-31 (1990).
109. Lemire JM: 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/lmice. Autoimmunity 123, 143-148 (1992).
110. Vaisberg MW, Kaneno R, Franco MF, Mendes NF: Influence of colecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice. J. Clin. Lab. Anal. 14, 91-96 (2000).
111. Barnes TC, Bucknall RC: Vitamin D deficiency in a patient with systemic lupus erythematosus. Rheumatology 43, 393-394 (2004).
112. Huisman AM, White KP, Algra A et al.: Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J. Rheumatol. 28, 2535-2539 (2001).
113. Muller K, Kriegbaum NJ, Baslund B, Sorensen OH, Thyman M, Bentzen K: Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin. Rheumatol. 14, 397-400 (1995).
114. Carvalho JF, Blank M, Kiss E, Tarr T, Amital H, Shoenfeld Y: Anti-vitamin D, vitamin D in SLE. Preliminary Results. Ann. NY Acad. Sci. 1109, 550-557 (2007).
115. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS: Vitamin D deficiency in systemic lupus erythematosus. Autoimmun. Rev. 5, 114-117 (2006).
116. Thudi A, Yin S, Wandstrat AE, Li Q-Z, Olsen NJ: Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am. J. Med. Sci. 335, 99-104 (2008).
117. Cutolo M, Otsa K: Vitamin D, immunity and lupus. Lupus 17, 6-10 (2008).
118. Borba VZ, Vieira JG, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M: Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos. Int. (2008) (Epub ahead of print).
119. McCarty DJ, Manzi S, Medsger TA, Ramseygoldman R, Laporte RE, Kwoh CK: Incidence of systemic lupus erythematosus: race and gender differences. Arthritis Rheum. 38, 1260-1270 (1995).
120. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C: Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology 47, 920-923 (2008).
121. Renne J, Werfel T, Wittman M: Correspondence: high frequency of vitamin D deficiciency among patients with cutaneous lupus erythematosus. Br. J. Dermatol. 159, 485-486 (2008).
122. Dietrich T, Joshipura KJ, Dawson-Hughes B, Bischoff-Ferrari HA: Association between serum concentrations of 25- hydroxyvitamin D3 and periodontal disease in the US population Am. J. Clin. Nutr. 80, 108-113 (2004).
123. Bischoff Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson Hughes B: Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 84, 18-28 (2006).
124. Lappe JM, Travers Gustafson D, Davies KM, Recker RR, Heaney RP: Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 85, 1586-1591 (2007).
125. Cannell JJ, Hollis BW: Use of vitamin D in clinical practice. Altern. Med. Rev. 13, 6-20 (2008).
126. Trang H, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R: Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am. J. Clin. Nutr. 68, 854-858 (1998).
127. Romagnoli E, Mascia ML, Cipriani C et al.: Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J. Clin. Endocrinol. Metab. 93, 3015-3020 (2008).
128. Armas LA, Hollis BW, Heaney RP: Vitamin D2 is much less effective than vitamin D3 in humans. J. Clin. Endocrinol. Metab. 89, 5387-5391 (2004).
129. Holick MF, Biancuzzo RM, Chen TC et al.: Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J. Clin. Endocrinol. Metab. 93, 677-681 (2008).
130. Heaney RP, Davies KM, Chen TC, Holick MF, Barger Lux MJ: Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 77, 204-210 (2003).
131. Leventis P, Patel S: Clinical aspects of vitamin D in the management of rheumatoid arthritis. Rheumatology (Oxford) 47, 1617-1621 (2008).
132. Hathcock JN, Shao A, Vieth R, Heaney R: Risk assessment for vitamin D. Am. J. Clin. Nutr. 85, 6-18 (2007).